Conference
Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma
Authors
Trudel S; McCurdy A; Sutherland H; Louzada M; Venner C; White D; Kotb R; Mian H; Camacho F; Fu M
Name of conference
American Society of Hematology (ASH) Annual Meeting and Exposition
Conference place
Virtual
Conference start date
December 2, 2020
Conference end date
December 11, 2020